Table 2.
Occurrence of AKI in the first 30 d after the diagnosis of SARS-CoV and SARS-CoV-2
| Occurrence of AKI | SARS-CoVa n=1565 | SARS-CoV-2 n=814 | P valueb |
|---|---|---|---|
| Peak creatinine level median (range) | 86 (25–1975) | 82 (21–1137) | <0.001 |
| AKI, n (%) | <0.001 | ||
| No AKI | 1351 (86.3) | 748 (91.9) | |
| AKI stage 1 | 123 (7.9) | 54 (6.6) | |
| AKI stage 2 | 33 (2.1) | 3 (0.4) | |
| AKI stage 3 | 58 (3.7) | 9 (1.1) | |
| Presence of moderate to severe AKI, n (%) | 91 (5.8) | 12 (1.5) | <0.001 |
Baseline creatinine level was on the basis of the creatinine level before or upon hospital admission. Peak creatinine level was presented in median (range). Qualitative and quantitative differences between subgroups were analyzed by chi-squared or Fisher’s exact tests for categorical parameters and Mann–Whitney U test for continuous parameters, as appropriate.
a
A total of 20 patients who received RRT at diagnosis of SARS-CoV were not included in the analysis.
b
Mann–Whitney U test for continuous variable, and chi-squared or Fisher’s exact tests for categorical variables were used to compare patients infected by SARS-CoV and SARS-CoV-2.